Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3018510 | 0.90 | CCR1 (0.52) | CCR1NR1I2 | |
| SCHEMBL3018507 | 0.90 | CCR1 (0.52) | CCR1NR1I2 | |
| SCHEMBL10210775 | 0.89 | CCR1 (0.50) | CCR1NR1I2 | |
| SCHEMBL10169491 | 0.88 | CCR1 (0.50) | CCR1NR1I2 | |
| SCHEMBL2160191 | 0.88 | RORC (0.52) | CCR1NR1I2 | |
| SCHEMBL2160379 | 0.88 | CCR1 (0.49) | CCR1 | |
| SCHEMBL31088540 | 0.88 | TSHR (0.49) | CCR1 | |
| SCHEMBL31088542 | 0.88 | TSHR (0.49) | CCR1 | |
| SCHEMBL12399460 | 0.87 | CCR1 (0.61) | CCR1 | |
| SCHEMBL654564 | 0.86 | CCR1 (0.48) | CCR1NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663537-B2 | Chemokine receptor antagonists and methods of use | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9334283-B2 | CCR1 antagonists and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-9334283-B2 | CCR1 antagonists and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-9334283-B2 | CCR1 antagonists and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-20160031908-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2016-02-04 | — | — | US | disclosed |
| EP-2486013-B1 | PRODRUGS OF A PIPERIDINYL DERIVATIVE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2015-07-08 | — | — | EP | disclosed |
| EP-2486013-B1 | PRODRUGS OF A PIPERIDINYL DERIVATIVE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2015-07-08 | — | — | EP | disclosed |
| US-20150005338-A1 | CCR1 ANTAGONISTS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-01-01 | — | — | US | disclosed |
| US-20150005338-A1 | CCR1 ANTAGONISTS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-01-01 | — | — | US | disclosed |
| US-20150005338-A1 | CCR1 ANTAGONISTS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-01-01 | — | — | US | disclosed |
| EP-1562954-B1 | CCR1 ANTAGONISTS FOR THE TREATMENT OF I.A. DEMYELINATING INFLAMMATORY DISEASE | MILLENNIUM PHARM INC (US) | 2006-05-03 | — | — | EP | disclosed |
| EP-1448566-B1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | MILLENNIUM PHARM INC (US) | 2006-03-15 | — | — | EP | disclosed |
| US-20050288319-A1 | CCR1 antagonists and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. | 2005-12-29 | — | — | US | disclosed |
| EP-1562954-A1 | CCR1 ANTAGONISTS FOR THE TREATMENT OF I.A. DEMYELINATING INFLAMMATORY DISEASE | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-08-17 | — | — | EP | disclosed |
| US-20050070549-A1 | Chemokine receptor antagonists and methods of use thereof | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2005-03-31 | — | — | US | disclosed |
| EP-1448566-A2 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-08-25 | — | — | EP | disclosed |
| US-20040106639-A1 | CCR1 antagonists and methods of use therefor | MILLENNIUM PHARMACEUTICALS | 2004-06-03 | — | — | US | disclosed |
| WO-2004043965-A1 | CCR1 ANTAGONISTS FOR THE TREATMENT OF I.A. DEMYELINATING INFLAMMATORY DISEASE | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-05-27 | — | — | WO | disclosed |
| WO-2003045942-A2 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2003-06-05 | — | — | WO | disclosed |
| US-20020169155-A1 | A nitrogen-ring containing triheterocyclic compound is useful for treating a disease associated with aberrant leukocyte recruitment and/or activation | MILLENNIUM PHARMACEUTICALS, INC. | 2002-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288319-A1 | CCR1 antagonists and methods of use therefor | CCR1, CCRL2, CCR4 | CCR1 1/4885NR1I2 191/4885 |
| US-20020169155-A1 | A nitrogen-ring containing triheterocyclic compound is useful for treating a disease associated with aberrant leukocyte recruitment and/or activation | NFATC1, ELANE, NCF1 | CCR1 9/4885NR1I2 824/4885 |
| US-20160031908-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | ACKR3, CCR2, CXCR2 | CCR1 9/4885NR1I2 1140/4885 |
| US-20050070549-A1 | Chemokine receptor antagonists and methods of use thereof | ACKR3, CXCR2, CCL11 | CCR1 4/4885NR1I2 789/4885 |
| US-20040106639-A1 | CCR1 antagonists and methods of use therefor | CCR1, CCRL2, CCR4 | CCR1 1/4885NR1I2 159/4885 |
| US-20150005338-A1 | CCR1 ANTAGONISTS AND METHODS OF USE THEREOF | CCR1, CCR3, CCR4 | CCR1 1/4885NR1I2 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.